These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20585799)

  • 1. Ranibizumab for diabetic macular edema difficult to treat with focal/grid laser.
    Kotsolis AI; Tsianta E; Niskopoulou M; Masaoutis P; Baltatzis S; Ladas ID
    Graefes Arch Clin Exp Ophthalmol; 2010 Nov; 248(11):1553-7. PubMed ID: 20585799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study).
    Comyn O; Sivaprasad S; Peto T; Neveu MM; Holder GE; Xing W; Bunce CV; Patel PJ; Egan CA; Bainbridge JW; Hykin PG
    Am J Ophthalmol; 2014 May; 157(5):960-70. PubMed ID: 24531025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial.
    Brown DM; Ou WC; Wong TP; Kim RY; Croft DE; Wykoff CC;
    Ophthalmology; 2018 May; 125(5):683-690. PubMed ID: 29336896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of foveal capillary drop-out and previous panretinal photocoagulation for diabetic macular oedema treated with ranibizumab.
    Ebneter A; Wolf S; Zinkernagel MS
    Br J Ophthalmol; 2016 Mar; 100(3):365-70. PubMed ID: 26187951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.
    Mitchell P; Bandello F; Schmidt-Erfurth U; Lang GE; Massin P; Schlingemann RO; Sutter F; Simader C; Burian G; Gerstner O; Weichselberger A;
    Ophthalmology; 2011 Apr; 118(4):615-25. PubMed ID: 21459215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal/grid laser photocoagulation.
    Hirano T; Toriyama Y; Iesato Y; Imai A; Hirabayashi K; Nagaoka T; Takamura Y; Sugimoto M; Murata T
    Jpn J Ophthalmol; 2017 Jan; 61(1):51-60. PubMed ID: 27730425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results.
    ; Elman MJ; Qin H; Aiello LP; Beck RW; Bressler NM; Ferris FL; Glassman AR; Maturi RK; Melia M
    Ophthalmology; 2012 Nov; 119(11):2312-8. PubMed ID: 22999634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema.
    Nepomuceno AB; Takaki E; Paes de Almeida FP; Peroni R; Cardillo JA; Siqueira RC; Scott IU; Messias A; Jorge R
    Am J Ophthalmol; 2013 Sep; 156(3):502-510.e2. PubMed ID: 23795985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment.
    Do DV; Nguyen QD; Khwaja AA; Channa R; Sepah YJ; Sophie R; Hafiz G; Campochiaro PA;
    JAMA Ophthalmol; 2013 Feb; 131(2):139-45. PubMed ID: 23544200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.
    Pearce I; Banerjee S; Burton BJ; Chakravarthy U; Downey L; Gale RP; Gibson J; Pagliarini S; Patel J; Sivaprasad S; Andrews C; Brittain C; Warburton J;
    Ophthalmology; 2015 Sep; 122(9):1811-9. PubMed ID: 26150052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
    Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
    Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation.
    ; Googe J; Brucker AJ; Bressler NM; Qin H; Aiello LP; Antoszyk A; Beck RW; Bressler SB; Ferris FL; Glassman AR; Marcus D; Stockdale CR
    Retina; 2011 Jun; 31(6):1009-27. PubMed ID: 21394052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results.
    Payne JF; Wykoff CC; Clark WL; Bruce BB; Boyer DS; Brown DM;
    Br J Ophthalmol; 2021 Feb; 105(2):253-257. PubMed ID: 32303499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.
    Schmidt-Erfurth U; Lang GE; Holz FG; Schlingemann RO; Lanzetta P; Massin P; Gerstner O; Bouazza AS; Shen H; Osborne A; Mitchell P;
    Ophthalmology; 2014 May; 121(5):1045-53. PubMed ID: 24491642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
    Solaiman KA; Diab MM; Abo-Elenin M
    Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion.
    Tan MH; McAllister IL; Gillies ME; Verma N; Banerjee G; Smithies LA; Wong WL; Wong TY
    Am J Ophthalmol; 2014 Jan; 157(1):237-247.e1. PubMed ID: 24112635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up.
    Arevalo JF; Sanchez JG; Fromow-Guerra J; Wu L; Berrocal MH; Farah ME; Cardillo J; Rodríguez FJ;
    Graefes Arch Clin Exp Ophthalmol; 2009 Jun; 247(6):735-43. PubMed ID: 19189118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial.
    Bressler SB; Qin H; Melia M; Bressler NM; Beck RW; Chan CK; Grover S; Miller DG;
    JAMA Ophthalmol; 2013 Aug; 131(8):1033-40. PubMed ID: 23807371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.